Literature DB >> 19271231

Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimer's disease.

R Michael Dutescu1, Qiao-Xin Li, Jonathan Crowston, Colin L Masters, Paul N Baird, Janetta G Culvenor.   

Abstract

BACKGROUND: Retinal ganglion cell loss is considered to be a cause of visual impairment in Alzheimer;s patients. Alterations in amyloid precursor protein (APP) processing and amyloid-beta (Abeta) accumulation, key molecules associated with Alzheimer;s disease pathogenesis, may therefore contribute to retinal damage. We therefore investigated retinal APP processing and eye morphology in Alzheimer;s transgenic mouse models.
METHODS: Eyes and brain samples of 2- to 18-month-old transgenic mice expressing human APP with the double Swedish mutation (APPswe) (APP K595N/M596L)(Tg2576) were compared with eyes and brain tissue from wild-type background C57BL6xSJL controls. In addition, 6- to 12-month-old double transgenic mice over-expressing human APPswe and mutant presenilin 1 with exon 9 deletion (APPswe/PS1-dE9) were compared with background controls of C57BL6xC3H strain. Tissue samples were fixed in formalin for immunohistochemistry, and dissected retinal and cerebellar extracts were frozen for Western blotting and enzyme-linked immunosorbent assay (ELISA). Monoclonal antibodies 1E8 and WO2 were used for immunohistochemical detection of APP and Abeta, whereas Abeta 42/40 levels were assayed by ELISA. APP and processed fragments were detected biochemically by Western blotting with domain-specific antibodies, using antibody WO2 (Abeta) and rabbit antibody 369 to the C-terminal domain of APP.
RESULTS: Immunocytochemistry revealed strong cytoplasmic expression of APP and possibly Abeta in retinal ganglion cells and inner nuclear layer cells, and in lens and corneal epithelia for APP transgenic mice. Retinas from the APP transgenic mouse strains contained 18 to 70 kDa APP proteolytic products that were not detected in the cerebellum. We found a higher proportion of APP alpha-secretase generated C-terminal fragments in transgenic retinal tissues than beta-secretase-generated C-terminal fragments. Very low level Abeta was detected in transgenic retinas by ELISA; retinal Abeta 42 was 75 times less than for transgenic brain. Abeta was not detected in mouse retina by Western blotting in our study, indicating much less generation of Abeta in retina than brain tissue.
CONCLUSIONS: Alzheimer's mouse model retinas present with different APP proteolytic products and have a significantly lower production of amyloidogenic Abeta than found in brain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19271231     DOI: 10.1007/s00417-009-1060-3

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  32 in total

1.  Alzheimer disease PS-1 exon 9 deletion defined.

Authors:  G Prihar; A Verkkoniem; J Perez-Tur; R Crook; S Lincoln; H Houlden; M Somer; A Paetau; H Kalimo; A Grover; L Myllykangas; M Hutton; J Hardy; M Haltia
Journal:  Nat Med       Date:  1999-10       Impact factor: 53.440

2.  Co-expression of multiple transgenes in mouse CNS: a comparison of strategies.

Authors:  J L Jankowsky; H H Slunt; T Ratovitski; N A Jenkins; N G Copeland; D R Borchelt
Journal:  Biomol Eng       Date:  2001-06

3.  Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease.

Authors:  Lee E Goldstein; Julien A Muffat; Robert A Cherny; Robert D Moir; Maria H Ericsson; Xudong Huang; Christine Mavros; Jennifer A Coccia; Kyle Y Faget; Karlotta A Fitch; Colin L Masters; Rudolph E Tanzi; Leo T Chylack; Ashley I Bush
Journal:  Lancet       Date:  2003-04-12       Impact factor: 79.321

4.  Alzheimer's peptide: a possible link between glaucoma, exfoliation syndrome and Alzheimer's disease.

Authors:  S Janciauskiene; T Krakau
Journal:  Acta Ophthalmol Scand       Date:  2001-06

5.  The potential role of amyloid beta in the pathogenesis of age-related macular degeneration.

Authors:  Takeshi Yoshida; Kyoko Ohno-Matsui; Shizuko Ichinose; Tetsuji Sato; Nobuhisa Iwata; Takaomi C Saido; Toshio Hisatomi; Manabu Mochizuki; Ikuo Morita
Journal:  J Clin Invest       Date:  2005-09-15       Impact factor: 14.808

6.  Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets.

Authors:  Geneviève Evin; Aiqin Zhu; R M Damian Holsinger; Colin L Masters; Qiao-Xin Li
Journal:  J Neurosci Res       Date:  2003-11-01       Impact factor: 4.164

7.  Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice.

Authors:  K Hsiao; P Chapman; S Nilsen; C Eckman; Y Harigaya; S Younkin; F Yang; G Cole
Journal:  Science       Date:  1996-10-04       Impact factor: 47.728

8.  Alterations in beta-amyloid production and deposition in brain regions of two transgenic models.

Authors:  Emily J H Lehman; Laura Shapiro Kulnane; Bruce T Lamb
Journal:  Neurobiol Aging       Date:  2003-09       Impact factor: 4.673

9.  In vitro characterization of Pittsburgh compound-B binding to Lewy bodies.

Authors:  Michelle T Fodero-Tavoletti; David P Smith; Catriona A McLean; Paul A Adlard; Kevin J Barnham; Lisa E Foster; Laura Leone; Keyla Perez; Mikhalina Cortés; Janetta G Culvenor; Qiao-Xin Li; Katrina M Laughton; Christopher C Rowe; Colin L Masters; Roberto Cappai; Victor L Villemagne
Journal:  J Neurosci       Date:  2007-09-26       Impact factor: 6.167

10.  Tau in Alzheimer's disease and Down's syndrome is insoluble and abnormally phosphorylated.

Authors:  D P Hanger; J P Brion; J M Gallo; N J Cairns; P J Luthert; B H Anderton
Journal:  Biochem J       Date:  1991-04-01       Impact factor: 3.857

View more
  53 in total

1.  Common micro RNAs (miRNAs) target complement factor H (CFH) regulation in Alzheimer's disease (AD) and in age-related macular degeneration (AMD).

Authors:  Walter J Lukiw; Bhattacharjee Surjyadipta; Prerna Dua; Peter N Alexandrov
Journal:  Int J Biochem Mol Biol       Date:  2012-03-20

2.  Retinal amyloid peptides and complement factor H in transgenic models of Alzheimer's disease.

Authors:  Peter N Alexandrov; Aileen Pogue; Surjyadipta Bhattacharjee; Walter J Lukiw
Journal:  Neuroreport       Date:  2011-08-24       Impact factor: 1.837

Review 3.  Beta-amyloid sequelae in the eye: a critical review on its diagnostic significance and clinical relevance in Alzheimer's disease.

Authors:  T M Shah; S M Gupta; P Chatterjee; M Campbell; R N Martins
Journal:  Mol Psychiatry       Date:  2017-01-17       Impact factor: 15.992

4.  Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer's disease.

Authors:  Yosef Koronyo; David Biggs; Ernesto Barron; David S Boyer; Joel A Pearlman; William J Au; Shawn J Kile; Austin Blanco; Dieu-Trang Fuchs; Adeel Ashfaq; Sally Frautschy; Gregory M Cole; Carol A Miller; David R Hinton; Steven R Verdooner; Keith L Black; Maya Koronyo-Hamaoui
Journal:  JCI Insight       Date:  2017-08-17

Review 5.  Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology.

Authors:  Harald Hampel; Nicola Toschi; Claudio Babiloni; Filippo Baldacci; Keith L Black; Arun L W Bokde; René S Bun; Francesco Cacciola; Enrica Cavedo; Patrizia A Chiesa; Olivier Colliot; Cristina-Maria Coman; Bruno Dubois; Andrea Duggento; Stanley Durrleman; Maria-Teresa Ferretti; Nathalie George; Remy Genthon; Marie-Odile Habert; Karl Herholz; Yosef Koronyo; Maya Koronyo-Hamaoui; Foudil Lamari; Todd Langevin; Stéphane Lehéricy; Jean Lorenceau; Christian Neri; Robert Nisticò; Francis Nyasse-Messene; Craig Ritchie; Simone Rossi; Emiliano Santarnecchi; Olaf Sporns; Steven R Verdooner; Andrea Vergallo; Nicolas Villain; Erfan Younesi; Francesco Garaci; Simone Lista
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

6.  Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer's and Parkinson's disease patients.

Authors:  Cheng-Ying Ho; Juan C Troncoso; David Knox; Walter Stark; Charles G Eberhart
Journal:  Brain Pathol       Date:  2013-06-28       Impact factor: 6.508

7.  Progressive inflammatory pathology in the retina of aluminum-fed 5xFAD transgenic mice.

Authors:  A I Pogue; P Dua; J M Hill; W J Lukiw
Journal:  J Inorg Biochem       Date:  2015-07-20       Impact factor: 4.155

Review 8.  One protein, multiple pathologies: multifaceted involvement of amyloid β in neurodegenerative disorders of the brain and retina.

Authors:  Vivek Gupta; Veer B Gupta; Nitin Chitranshi; Sumudu Gangoda; Roshana Vander Wall; Mojdeh Abbasi; Mojtaba Golzan; Yogita Dheer; Tejal Shah; Alberto Avolio; Roger Chung; Ralph Martins; Stuart Graham
Journal:  Cell Mol Life Sci       Date:  2016-06-22       Impact factor: 9.261

Review 9.  Beta-Amyloid Precursor Protein (βAPP) Processing in Alzheimer's Disease (AD) and Age-Related Macular Degeneration (AMD).

Authors:  Yuhai Zhao; Surjyadipta Bhattacharjee; Brandon M Jones; James M Hill; Christian Clement; Kumar Sambamurti; Prerna Dua; Walter J Lukiw
Journal:  Mol Neurobiol       Date:  2014-09-10       Impact factor: 5.590

10.  Amyloid beta deposition related retinal pigment epithelium cell impairment and subretinal microglia activation in aged APPswePS1 transgenic mice.

Authors:  Zhi-Zhang Dong; Juan Li; Yi-Feng Gan; Xue-Rong Sun; Yun-Xia Leng; Jian Ge
Journal:  Int J Ophthalmol       Date:  2018-05-18       Impact factor: 1.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.